KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.80

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Yeong Jer Lim, Victoria Ward, Anthony Brown, Eloise Phillips, Barbara Kronsteiner, Tom Malone, Daisy Jennings, Saoirse Healy, Stephanie Longet, Timothy James, Paul Thomson, Liam Farrell, Melanie Oates, Richard Jackson, Andrew Morrison, Matthew Burns, Miles Carroll, Paul Klenerman, Lance Turtle, Dean Naisbitt, Malcolm Rhodes, Kate Robinson, Simona Gatto, Moya Young, Kim Linton, Toby A Eyre, David W Eyre, Susanna Dunachie, Eleanor Barnes, Andrew Pettitt

Br J Haematol 205(2) 440-451

PMID38867615
PMCID-
DOI10.1111/bjh.19562
发表日期2024-06-13
入排依据:The record describes a Phase III randomized trial in follicular lymphoma, but the reported analysis is on vaccine immunogenicity, not a primary or key secondary time-to-event efficacy endpoint like OS or PFS. It is a secondary analysis within a larger trial, not the primary efficacy report.
摘要

摘要

Immune responses to primary COVID-19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016-004010-10). COVID-19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatment comprising rituximab (depletes B cells) and either bendamustine (depletes CD4+ T cells) or cyclophosphamide-based chemotherapy. Blood samples obtained after vaccine doses 1 and 2 (V1, V2) were analysed for antibodies and T cells reactive to the SARS-CoV-2 spike protein using the Abbott Architect and interferon-gamma ELISpot assays respectively. Compared to 149 healthy controls, patients with FL exhibited lower antibody but preserved T-cell responses. Within the FL cohort, multivariable analysis identified low pre-treatment serum IgA levels and V2 administration during induction or maintenance treatment as independent determinants of lower antibody and higher T-cell responses, and bendamustine and high/intermediate FLIPI-2 score as additional determinants of a lower antibody response. Several clinical scenarios were identified where dichotomous immune responses were estimated with >95% confidence based on combinations of predictive variables. In conclusion, the immunogenicity of COVID-19 vaccines in FL patients is influenced by multiple disease- and treatment-related factors, among which B-cell depletion showed differential effects on antibody and T-cell responses.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。